Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Vyome Holdings ( (HIND) ) is now available.
On October 28, 2025, Vyome Holdings, Inc. held its 2025 Annual Meeting of Stockholders, where 77.52% of shares were represented. During the meeting, Krishna K. Gupta, Dr. Shiladitya Sengupta, and Mr. Stash Pomichter were elected as Class I directors until 2028. The stockholders approved the 2025 Equity Incentive Plan and ratified Kreit & Chiu CPA LLP as the independent accounting firm for 2025. Additionally, the compensation of named executive officers was approved on a non-binding, advisory basis.
The most recent analyst rating on (HIND) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Vyome Holdings stock, see the HIND Stock Forecast page.
Spark’s Take on HIND Stock
According to Spark, TipRanks’ AI Analyst, HIND is a Underperform.
ReShape Lifesciences is facing significant financial challenges, with persistent losses, negative equity, and cash flow issues. The technical indicators show a bearish trend with potential oversold conditions. Valuation is poor due to a negative P/E ratio. Despite some positive developments highlighted in the earnings call, such as revenue growth and cost reductions, the overall outlook remains concerning due to financial instability and competitive pressures. The recent board resignation further complicates the situation by potentially affecting compliance and investor confidence.
To see Spark’s full report on HIND stock, click here.
More about Vyome Holdings
Average Trading Volume: 546,444
Technical Sentiment Signal: Strong Sell
Current Market Cap: $29.56M
Find detailed analytics on HIND stock on TipRanks’ Stock Analysis page.